Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Introduction Interstitial lung disease (ILD) patients may develop a progressive phenotype usually characterised by ...

Scientists have discovered that a rare immune cell type in the lungs, called NAMs, plays a crucial role in surviving COVID-19 ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

The first comprehensive analysis of three lung diseases across the England, Wales, Scotland, and Northern Ireland has been ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...